Share Email Print
cover

Proceedings Paper

Preliminary study on novel targeted anti-tumor drug aminoglucose based-doxorubicin
Author(s): Siwen Li; Chang Liu; Yue-qing Gu
Format Member Price Non-Member Price
PDF $14.40 $18.00

Paper Abstract

In order to improve Doxorubicin (Dox) targeting in vivo and reduce toxicity, use the targeting ligand 2-deoxy-aminoglucose (2DG) to modify Doxorubicin to form a new anti-tumor drug. The products was charactered by 1H-NMR, MS, and the targeting research by near-infrared imaging. Compared with Dox , the product treating MCF-7 and U87MG cells shows higher antitumor activity in vitro by MTT assay. In conclusion, the modified product effectively enhance the targeting and pharmacodynamics in contrast with Dox, and it would be a potential therapeutic drug for cancer.

Paper Details

Date Published: 17 September 2014
PDF: 7 pages
Proc. SPIE 9230, Twelfth International Conference on Photonics and Imaging in Biology and Medicine (PIBM 2014), 923019 (17 September 2014); doi: 10.1117/12.2068712
Show Author Affiliations
Siwen Li, China Pharmaceutical Univ. (China)
Chang Liu, China Pharmaceutical Univ. (China)
Yue-qing Gu, China Pharmaceutical Univ. (China)


Published in SPIE Proceedings Vol. 9230:
Twelfth International Conference on Photonics and Imaging in Biology and Medicine (PIBM 2014)
Qingming Luo; Lihong V. Wang; Valery V. Tuchin, Editor(s)

© SPIE. Terms of Use
Back to Top